| Identification | Back Directory | [Name]
5-Thiazolidineacetic acid, 2-[(2Z)-2-[[4-(1-methylethyl)phenyl]methylene]hydrazinylidene]-4-oxo-, (2Z)- | [CAS]
2242480-48-2 | [Synonyms]
5-Thiazolidineacetic acid, 2-[(2Z)-2-[[4-(1-methylethyl)phenyl]methylene]hydrazinylidene]-4-oxo-, (2Z)- | [Molecular Formula]
C15H17N3O3S | [MOL File]
2242480-48-2.mol | [Molecular Weight]
319.38 |
| Chemical Properties | Back Directory | [Boiling point ]
506.3±52.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 62.5 mg/mL (195.69 mM; Need ultrasonic) | [form ]
Solid | [pka]
3.81±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity[1]. | [Biological Activity]
VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity[1].
VPC-18005 is found to inhibit pETS-luc reporter activity in PNT1B-ERG and VCaP cells with IC50 values of 3 and 6 μM, respectively[1].VPC-18005 could suppress ERG reporter activity without exhibiting overt cytotoxicity[1].VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro[1].VPC-18005 can antagonize the metastatic potential of ERG-expressing prostate cells[1].The exposure of larvae to 1 or 10 μM of VPC-18005 produced a 20-30% decrease in the dissemination of cancer cells in zebrafsh[2]. | [storage]
4°C, protect from light | [References]
[1]. Miriam S Butler, et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. 2017 Jun 27;8(26):42438-42454.[2]. Haneen Amawi, et al. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer Chemother Pharmacol. 2021 Mar;87(3):311-325. |
|
|